This study was a prospective audit of patients receiving either intravenous induction of anaesthesia with propofol 2 mg/kg or inhalational induction using 8% sevoflurane for patients undergoing electroconvulsive therapy (ECT). All patients received inhaled 50% nitrous oxide. The anaesthetic agent was determined by psychiatrist preference. Each psychiatrist nominated only one induction technique for all his or her patients. Seventy treatments were studied in each group. Induction time was longer in the sevoflurane group. The time from commencing induction to loss of verbal contact was [mean (SD)] 64 (29.9) seconds for sevoflurane and 36 (33.6) seconds for propofol (P=0.001). Time to loss of eyelash reflex was 82 (32.6)s for sevoflurane and 44 (17.9)s for propofol (P<0.001). The duration of seizure activity was longer in sevoflurane patients, 35 (17.8)s, compared with 20 (9.8)s in the propofol group (P< 0.001). Discharge times were similar. Minor adverse effects occurred in three patients, all in the sevoflurane group (one bradycardia and two episodes of post-procedural nausea). There were no major adverse events in either group. Propofol and sevoflurane both appear to be suitable agents for induction of anaesthesia for ECT.
Electroconvulsive therapy (ECT) is provided for patients with severe schizophrenia and/or profound depression, unresponsive to medical management, or as initial therapy of severe depression with a risk of suicide while medical management is instituted. Anaesthesia is required to provide brief sedation and muscle relaxation to prevent injury due to the induced seizure. The agents used should be of short duration to provide rapid recovery and should not reduce seizure duration 1 . Thiopentone 2 and methohexital 3 have both been used for sedation for ECT but thiopentone may delay recovery and methohexital fails to suppress the cardiovascular response to ECT. Propofol provides rapid onset, good suppression of the cardiovascular response to ECT and rapid recovery but is painful to inject and may reduce seizure duration if not quality 4 .
Sevoflurane is a non-pungent volatile anaesthetic with a low blood-gas partition coefficient. Inhalational induction with sevoflurane takes longer than intravenous induction with propofol but the incidence of apnoea is reduced, transition to spontaneous ventilation is smoother and recovery is faster with sevoflurane 5 . Sevoflurane has been reported to have proconvulsant activity 6 and is thus unlikely to reduce the duration of seizures induced by ECT. The only study of sevoflurane use in ECT has been in concentrations of 1 to 2 MAC together with thiopentone induction 7 . The use of sevoflurane as a sole agent for ECT has not been described previously.
This study was an audit undertaken to compare inhalational induction with sevoflurane to intravenous induction with propofol in patients with severe depression requiring ECT.
MATERIALS AND METHODS
The ethics committee of the University of Natal, Medical Faculty, approved the study. The treating psychiatrist obtained consent for the performance of ECT from the patient or their next of kin. The treating psychiatrist also explained the mode of anaesthesia to be used according to their preference. Informed consent for the use of clinical data for audit purposes was obtained from each participating patient by the anaesthesiologist. Where patients were not considered competent to give consent this was obtained from the treating psychiatrist as well as the next of kin if possible. All patients were studied from the start of their series of ECT treatments. No patient had received a series of ECT treatments within three months of the study. The use of concomitant psychotropic medication varied according to disease severity and the preference of the treating psychiatrist. Patients were allocated to anaesthesia with nitrous oxide and either intravenous propofol or inhaled sevoflurane according to the preference of the treating psychiatrist. According to their usual practice, each psychiatrist involved in the audit consistently requested either inhaled sevoflurane or propofol based anaesthesia. This resulted in approximately equal numbers of patients being exposed to each treatment.
Patients were excluded from the trial if they were considered to be at risk for malignant hyperpyrexia or had known or suspected difficult airways.
The primary aim of the study was to determine the effect of the anaesthetic induction used on the duration of seizure activity induced by ECT. Secondary aims included determination of induction and emergence times, total duration of ECT treatment and the occurrence of adverse events. Data was collected prospectively and treatment did not vary from normal practice.
Patients were not given premedication but did receive their routine medication including psychiatric drugs. Intravenous access was established before induction and patients were monitored continuously with ECG, pulse oximetry and sidestream capnography. Non-invasive blood pressure was measured every two minutes. Heart rate, blood pressure and arterial haemoglobin oxygen saturation were recorded before induction and immediately following ECT. Episodes of arrhythmia, bradycardia (<50 beats per minute), desaturation (<96%) and hypotension (>20% decrease from baseline) or hypertension (>20% increase from baseline) were noted.
All patients were given 50% nitrous oxide in oxygen via a Mapleson A circuit at 8 l/min. After application of the facemask, either propofol 2 mg/kg was given intravenously or 8% sevoflurane was added to the inspired gas mixture. Patients were assessed at 15-second intervals from commencement of induction of anaesthesia for loss of verbal contact (loss of response to the command "Open your eyes") and loss of eyelash reflex. The times to each of these endpoints were recorded. Upon loss of the eyelash reflex, succinylcholine 0.4 mg/kg was given. In patients given propofol, if the eyelash reflex did not disappear, succinylcholine was given 45 seconds after injection and the fact that the reflex remained present was recorded. Following fasciculation a standard electroconvulsive current was applied bitemporally. The ECT treatments were similar for all patients. The clinical duration of the resulting seizure, as evidenced by peripheral tonic-clonic movements, was recorded.
Following termination of seizure activity, inhaled anaesthetic agents were discontinued, 100% oxygen administered and the airway maintained. If apnoea persisted for longer than three minutes after the seizure, or the haemoglobin oxygen saturation declined to 96%, ventilation was manually assisted. The time from the administration of succinylcholine to return of spontaneous ventilation was recorded. Times to first response to verbal command ("Open your eyes") as well as time to discharge to the ward were recorded.
Discharge was allowed when the patient was able to maintain arterial haemoglobin oxygen saturation >96% without supplemental oxygen, was able to respond appropriately to commands and was not nauseated.
The presence of side effects such as headache and postoperative nausea and vomiting were noted.
Patients remained in their allocated groups for all the treatments they received.
STATISTICAL ANALYSIS
The primary comparison was between inhalational induction with sevoflurane and intravenous induction with propofol. Statistical methods employed were univariate statistics. Differences in quantitative variables were assessed using Student's t-test. The tests of significance for categorical variables were based on the Chi-squared test. The variance inflation factor was computed and used to take into account the potential design effect of repeated measurements within individuals. In this way, the variances were inflated according to the corresponding inflation factor. The tests of significance are based on the adjusted standard errors. The means (standard deviations) are reported. All P values were based on a two-sided test. P values <0.05 were considered significant.
Sample size calculation determined that at least 50 treatments per group would be required to detect a 10-second difference in the duration of seizures between the groups, assuming a standard deviation of 15 seconds, with a power of 90% and 5% significance level (two-tailed) level.
RESULTS
Seventy treatments were studied in each group. No patient was excluded from the study. The sevoflurane group consisted of 23 patients while the propofol group had 24 patients. No patient received more than five treatments and only four patients received a single treatment. There were 7 males in the sevoflurane group compared with 3 males in the propofol group. There were 16 females in the sevoflurane and 21 females in the propofol group. The age distribution did not differ between the sevoflurane group and propofol group (Table 1) .
Induction times, both to loss of verbal contact and eyelash reflex were significantly longer in the sevoflurane group compared with the propofol group (Table 2 ). In 12 treatments, patients receiving propofol failed to lose their eyelash reflex.
The duration of seizure activity was significantly longer in sevoflurane treated patients compared with those treated with propofol ( Table 2) .
Following ECT, patients who received propofol took longer to breathe spontaneously and more of them required assisted ventilation.
Sevoflurane patients responded to verbal commands earlier (Table 3) .
Patients in the sevoflurane group had higher systolic blood pressures before treatment and a significant increase following ECT. There was no significant change in systolic blood pressure in propofol treated patients (Figure 1 ).
There were no episodes of arterial haemoglobin oxygen desaturation to <96% during or after ECT and heart rates did not differ significantly between the groups before or after treatment.
There were no major adverse events in either group. Three minor adverse events occurred. One patient in the sevoflurane group developed bradycardia following ECT, which responded to a single dose of atropine 0.3 mg. Two patients who received sevoflurane had mild nausea which responded to a single intramuscular dose of prochlorperazine 12.5 mg.
DISCUSSION
The mechanism of the beneficial effect of ECT in psychiatric patients is uncertain. The effect of anaesthetic agents on ECT is commonly assessed by their effect on the duration of the induced seizure 4 . This effect is also influenced by disease severity and the concomitant psychotropic medication prescribed to treat the acute disease and prevent relapse.
Psychiatric patients undergoing ECT may be good candidates for inhalational induction. The establishment of intravenous access may be difficult and traumatic. Inhalational anaesthesia with a short- acting, non-pungent agent such as sevoflurane may be performed before establishment of intravenous access and is of sufficiently short duration to minimize patient distress. This study was unable to demonstrate these benefits as intravenous access was established before induction in all cases. The increase in exposure to sevoflurane associated with establishing intravenous access after induction with sevoflurane could increase recovery times compared to briefer exposure to sevoflurane. Our audit methodology used to compare the techniques has both advantages and disadvantages compared to a randomized controlled trial. The advantages are mainly in completeness of data collection in the study sample as all patients can be studied. A truly randomized study in psychiatric patients with severe illness may not be possible due to the inability to gain appropriate informed consent from such patients. Although ethical approval may be gained for consent from a legal guardian or no consent in cases of clear clinical equivalence of the treatments being studied, these conditions may be difficult to fulfil or not available and significantly limit recruitment or the nature of the study. Our ethically approved audit of our current practice allowed complete recruitment and took advantage of the clinical preferences of the treating psychiatrists to create the groups for omparison.
The main disadvantage of our audit methodology is the potential for bias or confounding relating to the link between induction technique and treating psychiatrist. The severity of disease and concomitant medication prescribed by the treating psychiatrists was not standardized. Despite this, particularly in the absence of randomized controlled trials, we believe our data is of interest, and a difference between the induction agents remains the most plausible reason for differences in the results. The situation in our centre, where inhalational induction is requested by one group of psychiatrists and intravenous induction by another group, provided the opportunity to compare these techniques without selection bias due to the preference of the anaesthetist involved. The data was collected prospectively, and provides a description of differences in anaesthetic endpoints occurring during normal clinical practice using two methods of anaesthetic induction.
Discussions with the psychiatrists concerned have shown that their preference is based on two main issues. The psychiatrists who prefer intravenous induction consider that the duration of the ECT procedure is shorter using propofol. The psychiatrists who prefer sevoflurane feel the procedure is less traumatic for their patients, as awake intravenous access is not required. Neither group feels the induction method chosen influences the efficacy of the ECT.
This study demonstrates that sevoflurane induction provided average induction times less than a minute longer than intravenous induction with propofol, offset by average recovery times that were shorter by just over a minute. Overall average discharge times did not differ. These results are consistent with a previous comparison of sevoflurane with propofol for anaesthesia for cystoscopy 5 .
Sevoflurane administration was associated with longer seizure activity than propofol. This is consistent with a study showing increased epileptogenic activity in epileptic children anaesthetized with sevoflurane 7 . The significance of seizure duration in ECT is uncertain 8 but there is a perception amongst psychiatrists that short seizure duration is associated with a less satisfactory outcome. There is, however, no consensus on whether longer seizure duration improves outcome or on the optimal length of seizure duration. Any therapeutic benefit due to the longer seizure duration shown with sevoflurane in this study, in terms of reducing numbers of ECT treatments required and relapse rates after ECT treatment, will require a larger study with longer follow-up and better control of concomitant medication.
Adverse events associated with sevoflurane administration were mild and transient. The two patients requiring antiemetic treatment in the sevoflurane group compared with none in the propofol group, while not significant, is consistent with the previously described increased incidence of postoperative nausea and vomiting with sevoflurane compared with propofol 9 . This may influence the choice of anaesthetic in individual patients with a strong history of postoperative nausea and vomiting.
ECT causes a generalized discharge from the CNS, including the vasomotor centre, usually resulting in significant tachycardia and hypertension. Propofol tends to minimize this response 4 . Sevoflurane, which has minimal cardiovascular effects, would be expected to not modify this response as much as propofol. This is consistent with our results, where sevoflurane, but not propofol, was associated with an increase in systolic blood pressure after the seizure. This effect is similar to that seen with etomidate 10 , which also has minimal cardiovascular effects. The baseline higher blood pressure in the sevoflurane group could also plausibly be postulated to be asso-ciated with the greater blood pressure response to ECT in the sevoflurane group.
In this study both sevoflurane and propofol proved acceptable for use with nitrous oxide as an anaesthetic agent for ECT.
